医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

MELBOURNE, Australia & PHILADELPHIA, Pa.

Australian antibody company Avipep has today announced the clinical results of the imaging study of AVP04, the company’s treatment for advanced prostate and ovarian cancers, will be presented at the world’s largest cancer therapies conference AACR in Philadelphia, USA, on Monday (US EDT).

The Study’s principal investigator Professor Andrew Scott, Scientific Director of the Melbourne based PET Centre at Austin Health and Lab Head at the Olivia Newton-John Cancer Research Institute will present the data as part of the AACR session Clinical Trials of Novel Therapeutics.

AVP04 is a novel engineered antibody, an Avibody^TM, which targets the TAG72 cancer marker known to be highly expressed in a majority of prostate and ovarian cancers as well as other tumor types.

The current clinical study provides compelling data on the safety and biodistribution of radiolabelled AVP04 in patients and strongly supports the potential for AVP04, and Avibodies in general, as a platform for imaging and therapy. The study will be submitted to a peer-review journal with the findings to be made available after Professor Scott’s presentation.

The study was conducted with Cancer Trials Australia at Austin Health and the Peter MacCallum Cancer Centre in Melbourne, Australia.

Avipep Chief Executive Officer, Dr Peter Smith said: “To have the data from this important study featured at the world’s most influential cancer therapy conferences is an indication of the novelty and promise of AVP04 and our AVibodies platform technology. We are grateful to the study participants, their families and all of the medical personnel involved in the conduct of the study.”

Dr Smith will be in Philadelphia for the AACR meeting and available to meet.

About Avipep: A privately owned company based in Melbourne Australia, a spin-out from the Commonwealth Science and Industry Research Organisation (CSIRO). Avipep is developing Avibodies as a platform for targeting cells in the body with a focus on antibody-drug conjugates (ADC) for the treatment of cancer. Avibodies consist of the key binding domains of an antibody thereby sharing the same selectivity and avidity for its target. Clinical data suggests that a greater proportion of an injected dose of an Avibody is deposited in the tumor when compared to whole antibodies with potential advantages in terms of efficacy and safety. Different payloads can be conjugated to specifically engineered sites on Avibodies producing homogeneous products for radio-immunotherapy (RIT), ADC drug therapy, molecular imaging or for the creation of immuno-conjugates and bi-specifics.